Medical
education in Bern and Geneva, MD 1978. PhD 1984 and FMH in pathology 1988 in
Basel.
Positions
held: 1974 Immunology University of Bern, 1979 Pharmacology, Sandoz Pharma
Basel, 1991 University of Zurich, Pharmacology-Toxicology, Immunology
University Cape Town, RSA. Since 2001 Director of research, CNRS Immunology,
Orleans, France with active research, and advisor of several pharmaceutical
companies. Founder of IBR Inc, Artimmune SAS and Phenotec AG.
Research Interests:
Mechanisms of inflammation, especially respiratory inflammation, fibrosis,
emphysema and COPD, but also in skin, hepatic, intestinal, renal and CNS
inflammation. Cell death, innate immune danger sensing and cGAS/STING, ROS and
Inflammasome activation in models of human inflammatory diseases and tumor
development, role of microbiome, metabolome, neuroinflammation/degeneration and
ageing.
Role of TNF and IL-1
members, in cell death and IL-33 and T2 / T17 polarization and differentiation.
PB drug candidate
Stable butyrate to treat chronic lung inflammatory disease
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."